Arizona Liver Health

What Arizona Liver Health does

Arizona Liver Health (ALH) is a private, multi-site hepatology and clinical research practice founded in 2017 and headquartered in Tucson, Arizona, operating five clinic locations across the state (Chandler x2, Peoria, Tucson, Flagstaff). The practice provides comprehensive diagnostic, evaluation, and treatment services for liver disease — including fatty liver disease (MASLD/MASH), viral hepatitis, autoimmune and genetic liver disease, alcohol-associated liver disease, cirrhosis, and liver cancer — anchored by a team of board-certified transplant hepatologists and advanced practice providers. Its core diagnostic platform is FibroScan, an FDA-approved vibration-controlled transient elastography device that delivers non-invasive liver stiffness and fat quantification in approximately ten minutes, offered free of charge to new patients as a freemium entry point.

ALH generates revenue primarily through insurance-billed clinical services across per-visit encounters, supplemented by a specialty pharmacy with prior authorization support and 340B program participation, Phase 1 through Phase 3 clinical trial sponsor payments, and telemedicine/mobile phlebotomy revenue via the VEN Centers sister organization focused on viral hepatitis and HIV prevention (PrEP/PEP). It has built a nine-drug specialty medication portfolio spanning first-in-class MASH therapy (Rezdiffra), PBC treatments (Iqirvo, Livdelzi, Ocaliva), hepatitis B/C antivirals (Vemlidy, Vosevi, Epclusa, Mavyret), and hepatic encephalopathy therapy (Xifaxin), positioning the practice as an early-access site for newly approved hepatology drugs. Go-to-market combines provider referrals (PCP, GI, endocrinology, harm reduction), direct-to-patient outreach through community events (Liver Life Walk, Global Fatty Liver Day), content marketing via blog and Instagram, and a free FibroScan funnel that converts screened patients into longitudinal care relationships.

Name

Arizona Liver Health

Legal name

Arizona Liver Health

Website

https://azliver.com

Company type

Private

Founded year

2017

Operating status

Operating

Headcount range

101–250 employees

Short description

Arizona Liver Health is a private multi-site hepatology practice founded in 2017, operating five Arizona clinics that diagnose and treat liver disease (MASLD/MASH, viral hepatitis, autoimmune, cirrhosis, liver cancer) using FibroScan, specialty medications, and Phase 1–3 clinical trials, serving individual patients and referring providers across the state.

Ownership category

akta.pro rank

Product category

Hepatology Services

NAICS

Medical and Diagnostic Laboratories (62151), Diagnostic Imaging Centers (621512), Pharmacy Benefit Management and Other Third Party Administration of Insurance and Pension Funds (524292)

SIC

Services-Offices & Clinics Of Doctors Of Medicine (8011), Services-Medical Laboratories (8071), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)

akta.pro primary industry

Transplant Hepatology (HLAKAEAK)

akta.pro secondary industries

Hepatology (Viral Hepatitis) (HLAKAGAC), Liver & GI Clinical Research (Trials Centers) (HLAKAEAL), Gastroenterology & Hepatology Pharmaceuticals (HLAIAAAI), Rare Gastroenterology & Hepatology Disorder Therapies (HLAIAIAL)

Keywords

• Hepatology clinical services
• Liver disease treatment
• Non-invasive liver diagnostics
• Clinical trial enrollment
• Specialty pharmacy services

Headquarters

HQ city

Tucson

HQ country

United States

HQ region

North America

Offices5 records

Markets served

GTM type

B2C

Offering type

Services

Cost components

Personnel, Operations, Supply Chain, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Clinical Services Revenue: Revenue generated from patient consultations, diagnostic services, and treatments for liver diseases. Billed to insurance or paid by private-pay patients.
2. Clinical Trial Compensation: Participants in clinical trials may receive compensation for time and travel. Phase 1 participants may receive up to $4,000.
3. Pharmacy Services: ALH provides specialty pharmacy with prior authorization support. Operates 340B program for community outreach.

Pricing tiers

Go-to-market motion2 records

Distribution channels4 records

Marketing channels5 records

Core offering

Arizona Liver Health operates a multi-site hepatology practice that diagnoses and treats liver diseases (fatty liver disease/MASLD/MASH, viral hepatitis, autoimmune and genetic liver disease, alcohol-associated liver disease, cirrhosis, and liver cancer). It delivers outpatient clinical care supported by FibroScan diagnostics, a portfolio of FDA-approved liver medications, specialty pharmacy services, telemedicine through VEN Centers, and an embedded Phase 1–3 clinical trial program.

Product overview

Arizona Liver Health (ALH) is a multi-site hepatology and clinical research practice offering a comprehensive portfolio of liver disease services across five Arizona locations. The core offering combines clinical patient care (FibroScan diagnostics, medication management across nine branded pharmaceuticals, nutrition counseling) with an extensive Phase 1-3 clinical trial infrastructure. Related services include VEN Centers (viral hepatitis/HIV specialty), an in-house specialty pharmacy with financial assistance, and patient education programs. The organization operates a physician referral network and accepts most major insurance plans plus self-pay patients.

Differentiator

Problem solved

Functional benefit

Brands

• VEN Centers: Specializes in diagnosing and treating viral Hepatitis and HIV through telemedicine, mobile phlebotomy, in-person appointments, and home medication delivery.
• Arizona Clinical Trials

Products and services

• Arizona Liver Health Clinical Services Comprehensive outpatient hepatology care including diagnosis, treatment, and disease management for patients with liver disease across Arizona, billed through major insurance plans or self-pay.
• FibroScan Liver Assessment Non-invasive ultrasound-based imaging using vibration-controlled transient elastography to measure liver stiffness and fatty infiltration (Cap Score) in approximately 10 minutes, offered as an alternative to liver biopsy for patients at risk of or diagnosed with liver disease.
• Phase 1 Clinical Trials First-in-human clinical trial program evaluating safety and dosage ranges of new liver disease therapies, with participants eligible for compensation.
• Phase 2–3 Clinical Trials Later-phase clinical trials evaluating efficacy and safety of liver disease treatments in patients with specific liver conditions.
• VEN Centers Viral Hepatitis and HIV Services Specialty centers diagnosing and treating viral hepatitis (including free hepatitis testing) and providing HIV PrEP/PEP prevention through virtual telemedicine visits, mobile phlebotomy, in-person appointments, and home medication delivery.
• ALH / VEN Specialty Pharmacy Services In-house specialty pharmacy supporting patients on liver disease specialty medications with prior authorization navigation, financial assistance, copay cards, and 340B program access.
• Liver Disease Medication Portfolio Prescribing and management of FDA-approved liver disease medications including Rezdiffra for MASH, Iqirvo and Livdelzi for PBC, Vemlidy for hepatitis B, Vosevi, Epclusa, and Mavyret for hepatitis C, Ocaliva for PBC, and Xifaxin for hepatic encephalopathy.
• Telemedicine Services Virtual healthcare consultations and remote follow-up visits for liver disease patients, particularly those receiving viral hepatitis care through VEN Centers.
• Nutrition and Lifestyle Education Programs Structured patient education programs covering Mediterranean, intermittent fasting, and ketogenic diets, nutrition in cirrhosis, and MASLD exercise plans to support lifestyle modification in liver disease management.

Quantifiable outcome

• Hepatitis C cure rates exceeding 95% with modern medications
• +3 more outcomes

Named customers2 records

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Partnerships

Seven partnerships are on record, tiered core and minor.

• American Liver FoundationcoreStrategic or Co-development PartnerArizona Liver Health partners with the American Liver Foundation for community outreach and awareness events. Dr. Justin Reynolds spoke at the Liver Life Walk Arizona 2025 event. ALH supports the foundation's mission to promote liver health education, research, and advocacy.
• VEN CenterscoreStrategic or Co-development PartnerVEN Centers was founded by the same experts who developed Arizona Liver Health clinics. VEN Centers specialize in diagnosing and treating viral Hepatitis and preventing HIV through telemedicine, mobile phlebotomy, in-person appointments, and home medication delivery. They share leadership and operational infrastructure with ALH.
• Madrigal PharmaceuticalsminorStrategic or Co-development PartnerArizona Liver Health provides access to Rezdiffra (resmetirom), Madrigal's FDA-approved treatment for MASH (fatty liver disease with moderate to severe fibrosis). Dr. Naim Alkhouri is featured in materials about this medication.
• IpsenminorStrategic or Co-development PartnerArizona Liver Health provides access to Iqirvo (elafibranor), Ipsen's FDA-approved treatment for primary biliary cholangitis (PBC) in adults who do not respond to or cannot tolerate ursodeoxycholic acid.
• Gilead SciencesminorStrategic or Co-development PartnerArizona Liver Health provides access to Livdelzi (seladelpar), Gilead's FDA-approved treatment for PBC, as well as Vemlidy (hepatitis B) and Vosevi (hepatitis C) medications.
• Gilead Sciences (Epclusa)minorStrategic or Co-development PartnerArizona Liver Health provides access to Epclusa (sofosbuvir/velpatasvir), Gilead's hepatitis C treatment with 98% cure rate in as few as 12 weeks.
• AbbVie (Mavyret)minorStrategic or Co-development PartnerArizona Liver Health provides access to Mavyret (glecaprevir/pibrentasvir), AbbVie's hepatitis C treatment with 98% cure rate in as few as 8 weeks.

Scale indicators5 records

Recent moves7 records

Expansion highlights5 records

Direct peers

• Borland Groover: Independent gastroenterology and hepatology specialty practice in Florida with research programs; comparable as a multi-location private hepatology practice with embedded clinical trials and proprietary diagnostic offerings.
• Capital Digestive Care: Largest independent gastroenterology group in the DC metro area with hepatology services and clinical research; comparable to ALH as a multi-site private GI/hepatology group with research integration.
• Texas Liver Institute: Largest independent hepatology and clinical research practice in Texas, providing specialty liver care and Phase 1-3 hepatology trials; directly comparable to Arizona Liver Health's hepatology-only, clinical-trial-integrated model, and explicitly mentioned in ALH team biographies.
• Digestive Health Associates of Texas (DHAT): Large independent GI specialty group in Texas with hepatology and research programs; comparable as a multi-site independent GI/hepatology practice with research and ancillary services.

Broad incumbents

• Mayo Clinic Arizona — Hepatology: Academic hepatology and liver transplant program headquartered in Phoenix (same market as ALH); comparable in service scope (full-spectrum hepatology including transplant) and competes directly for Arizona liver patients and trial placements.
• Gastro Health: Largest US gastroenterology specialty platform with embedded hepatology services across multiple states; comparable because hepatology is a core service line, and ALH represents the hepatology-concentrated model that Gastro Health consolidates in its multi-specialty GI footprint.
• United Digestive: PE-backed GI specialty platform operating physician groups and infusion/specialty services across the Southeast; comparable to ALH as a private-equity-aligned specialty group model with embedded research and ancillary services.
• One GI: PE-backed consolidated gastroenterology platform across the Mid-South; relevant as a parallel specialty-group consolidation model with hepatology services and ancillary revenue streams.

Regional players

• Illinois Gastroenterology Group: Independent multi-site GI specialty group in Illinois with hepatology and clinical research programs; comparable as a regional private specialty group model that does not directly overlap ALH's geography.
• Banner Health — Liver Transplant & Hepatology: Arizona-based integrated health system operating liver transplant at Banner/St. Joseph's (where ALH founders Manch and Reynolds previously led programs); directly comparable provider of transplant hepatology services in the same Arizona geography.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/@azliverhealth
• LinkedInlinkedin.com/company/arizona-liver-health
• Instagraminstagram.com/azliverhealth
• Xx.com/LiverArizona

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Subsidiaries2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Arizona Liver Health